Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous adipose-derived stromal vascular fraction (SVF) is an investigational cell therapy being developed by the Instituto de Investigación Hospital Universitario La Paz. It consists of a heterogeneous population of cells, including mesenchymal stem cells, endothelial progenitor cells, and immune cells, extracted from a patient's own adipose tissue via lipoaspiration. Unlike expanded adipose-derived stem cells (ASCs), SVF is processed and administered without cell culture expansion, typically through enzymatic digestion or mechanical dissociation. The therapy is administered via intralesional injection into the walls of rectovaginal fistulas, particularly in patients with Crohn's disease. The mechanism of action involves the local delivery of regenerative cells that promote angiogenesis, modulate the local immune response, and facilitate tissue repair to achieve fistula closure.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Autologous adipose-derived stromal vascular fraction (La Paz).